Endocrine Abstracts

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...

Introduction: Although 18F-FDG-PET has found wide application in the management of radio-refractory differentiated thyroid cancers (RAI-R-DTCs), alternative radiotracers, including 68Ga-PSMA have been recently evaluated. Prostate-specific membrane antigen (PSMA) is in fact overexpressed in the microvasculature of several solid malignancies including thyroid cancers.Aim: To compare the diagnostic performance between 68Ga-P...